What GNI Group does

GNI Group Ltd. (株式会社ジーエヌアイグループ) is a Tokyo-headquartered global biopharmaceutical group listed on the Tokyo Stock Exchange Growth Market under ticker 2160. Through consolidated subsidiaries in Japan, China, the United States, and Australia, the group operates an integrated value chain spanning drug discovery, clinical development, manufacturing, and commercialization. Its therapeutic focus is on unmet medical needs, with particular depth in fibrotic and rare diseases, anchored by pirfenidone-based assets for idiopathic pulmonary fibrosis (IPF) and thrombocytopenia, the TGF-β1 inhibitor F351, and avatrombopag maleate for hematology. In July 2026 GNI closed the ¥44.8 billion acquisition of Ayumi Pharmaceutical Holdings from a Blackstone-led shareholder group, instantly adding Japan's dominant acetaminophen franchise (approximately 83% domestic market share and ¥38.5 billion of FY March 2026 revenue) and bringing pro-forma projected revenue to approximately ¥65.2 billion for fiscal 2026.

The group's technology and product footprint is unusual in spanning high-cost Japan specialty pharma, China-based drug discovery and manufacturing through Beijing Continent and Cullgen (Gyre Therapeutics), and US-based medtech/biomaterials via Berkeley Advanced Biomaterials (ISO 13485:2016 certified) and Berkeley Biologics. Core branded assets include Ice Slurry / アイスーリュイ (pirfenidone for IPF), 康曲欣® / Kangquxin (pirfenidone capsule launched March 2025 in China for thrombocytopenia, with pneumoconiosis in development), and F351, which has been referenced in Nature Reviews Cancer. The platform is described as proprietary, leveraging high-quality, cost-efficient China operations as a structural advantage, and the group has committed publicly to AI utilization in drug discovery as a designated sustainability Materiality, though specific AI capabilities remain undisclosed.

Revenue mechanics are now a blend of (a) high-volume, low-margin generic acetaminophen sales in Japan via Ayumi's direct sales channel; (b) branded specialty pharmaceutical sales in China via Beijing Continent and the gyre/cullgen subsidiaries; and (c) emerging US medtech/biomaterials revenue. Pro-forma revenue is projected at ¥65.2 billion for fiscal 2026, with the IPO-listed entity headquartered in Tokyo and a recent cap-table reshape that brought Blackstone, Toho Holdings, and Hisamitsu Pharmaceutical in as new shareholders concurrent with the Ayumi acquisition. Pricing is not publicly disclosed. The customer base is highly fragmented end-user demand (patients and healthcare providers via distributors) rather than concentrated enterprise accounts, and the group's go-to-market combines direct Japan sales, China-based clinical/commercial operations, and limited licensing/co-development such as the Arvinas partnership.

Name

GNI Group

Legal name

株式会社ジーエヌアイグループ

Website

https://gnipharma.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

GNI Group is a Tokyo-headquartered biopharmaceutical company developing drugs for unmet medical needs. It operates across Japan, China, the US, and Australia, and holds Japan's dominant acetaminophen franchise via the recently acquired Ayumi Pharmaceutical.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Drug discovery services
• Pharmaceutical manufacturing
• Rare disease therapeutics
• Biopharmaceutical products
• Clinical drug development

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Japan): Revenue from Ayumi Pharmaceutical Holdings, which holds approximately 83% of Japan's domestic market share for acetaminophen products, with revenue of ¥38.5 billion for fiscal year ending March 2026.
2. Drug Discovery and Development Services: Revenue from new drug discovery and clinical development activities conducted primarily in China through subsidiaries, leveraging the company's proprietary discovery platform.
3. Combined Projected Revenue: The company projects combined revenue to reach approximately ¥65.2 billion by fiscal 2026 following the completion of the Ayumi Pharmaceutical acquisition.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

GNI Group Ltd. is a global healthcare company that operates a vertically integrated pharmaceutical business spanning drug discovery, clinical development, manufacturing, and sales through consolidated subsidiaries headquartered across Japan, China, the United States, and Australia. The company's core products include Pirfenidone (Ice Slurry / アイスリュウイ) for idiopathic pulmonary fibrosis, Kangquxin (康曲欣) for thrombocytopenia, avatrombopag maleate tablets, and F351 (a TGF-β1 inhibitor) under development for fibrotic diseases, alongside acetaminophen products distributed primarily in Japan through its recently acquired subsidiary Ayumi Pharmaceutical Holdings, which holds approximately 83% of Japan's domestic acetaminophen market share.

Product overview

GNI Group is a global healthcare company that operates a vertically integrated business model spanning drug discovery, clinical development, manufacturing, and sales. The company maintains operational bases in Japan, China, the US, and Australia. The core portfolio includes Ayumi Pharmaceutical (acquired in 2026, holding ~83% of Japan's acetaminophen market), the proprietary drug discovery platform leveraging AI and China-based operations, and key products like Ice Slurry (アイスーリュイ)/Pirfenidone for IPF treatment and 康曲欣® (Kangquxin) for thrombocytopenia. The company also operates a medtech segment including Berkeley Advanced Biomaterials LLC and Berkeley Biologics LLC. Recent acquisitions include Ayumi Pharmaceutical Holdings for ¥44.8 billion and plans to make Cullgen Inc. a wholly owned subsidiary through Gyre Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• Pirfenidone (Ice Slurry / アイスリュウイ) Idiopathic pulmonary fibrosis (IPF) treatment drug developed and marketed by Beijing Continent (Gyre Pharmaceuticals) in China, also under investigation for radiation-induced lung injury.
• Kangquxin (康曲欣) Pirfenidone Capsule Approved in China for thrombocytopenia (TP) treatment, launched by Beijing Continent in March 2025; also being developed for pneumoconiosis indication.
• Avatrombopag Maleate Salt Tablets Thrombocytopenia therapy that received sales approval from Gyre Therapeutics in July 2024 for the medtech product portfolio.
• F351 (TGF-β1 Inhibitor) A TGF-β1 inhibitor developed by Gyre Therapeutics/Cullgen, under research for various fibrotic diseases including liver fibrosis.
• Acetaminophen Products (Ayumi Pharmaceutical) Acetaminophen product portfolio distributed in Japan through Ayumi Pharmaceutical Holdings, holding approximately 83% of Japan's domestic market share for acetaminophen products.
• Berkeley Advanced Biomaterials LLC US-based medtech company specializing in biomaterials for the medical device industry, holding ISO 13485:2016 certification for quality management systems.
• Berkeley Biologics LLC US-based company within the medtech biomaterials group, operating alongside Berkeley Advanced Biomaterials LLC as part of GNI Group's medtech business.

Quantifiable outcome

• Combined projected revenue of ¥65.2 billion by fiscal 2026
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Partnerships

One partnership is on record.

• Ayumi Pharmaceutical Holdings Co., Ltd.coreStrategic or Co-development Partner · 2 July 2026GNI Group completed the acquisition of all shares of Ayumi Pharmaceutical Holdings Co., Ltd. for approximately ¥44.8 billion in enterprise value. Ayumi Pharmaceutical and its subsidiary have become wholly owned subsidiaries of GNI Group, with Ayumi holding approximately 83% of Japan's domestic market share for acetaminophen products and recording revenue of ¥38.5 billion for fiscal year ending March 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Genentech (Roche): Markets Esbriet (pirfenidone), the originator of the active ingredient in GNI's ice-pirfenidone product for IPF. Direct therapeutic competitor in IPF with vastly larger resources and global commercial reach.
• Shionogi: Mid-to-large Japanese pharmaceutical company with a focus on specialty therapeutics and global expansion. Comparable to GNI's Japanese pharma roots with specialty pharma ambitions, though at materially greater scale and with established global operations.
• Boehringer Ingelheim: Markets Ofev (nintedanib), the leading competing therapy for IPF. Major multinational pharma competitor whose resources dwarf GNI's IPF franchise ambitions globally.
• Vertex Pharmaceuticals: Specialty pharma leader focused on rare diseases (cystic fibrosis, sickle cell). Comparable business model archetype — focused R&D targeting small populations of high-unmet-need patients — that GNI's rare disease strategy aspires to emulate.

Direct peers

• Toho Holdings: Major Japanese pharmaceutical wholesaler that became a GNI shareholder. Comparable as a Japanese pharma industry participant, now serving as both a peer/strategic partner and a critical distribution channel for GNI's products in Japan.
• Hisamitsu Pharmaceutical: Japanese pharma company that became a GNI shareholder via the Ayumi acquisition. Comparable as a Japanese pharmaceutical company with consumer healthcare and specialty pharma operations, and now an aligned strategic partner.
• Mochida Pharmaceutical: Japanese specialty pharma with a portfolio spanning women's health, dermatology, and specialty therapeutics. Comparable to GNI in its mid-cap Japanese specialty pharmaceutical positioning and focus on differentiated therapeutic areas.
• Cullgen Inc. Wholly-owned GNI subsidiary (via Gyre Therapeutics) focused on TGF-β1 inhibitor F351 and targeted protein degradation for fibrotic diseases and oncology. Internal peer for GNI's R&D pipeline and an emerging platform biotech.
• Nippon Shinyaku: Japanese specialty pharmaceutical company with a strong focus on rare diseases and unmet medical needs, including orphan drug development. Highly comparable to GNI's specialty pharma positioning and rare disease focus, though operating at significantly larger scale.

Emerging players

• BioMarin Pharmaceutical: Mid-cap rare disease biotech with multiple orphan drug franchises. Comparable to GNI's specialty/rare disease business model and similar revenue scale, providing a useful benchmark for specialty pharma valuation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/GNIpharma
• YouTubeyoutube.com/@GNIpharma2160
• Instagraminstagram.com/gnipharma2160
• TikToktiktok.com/@gnipharma2160

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GNI Group